An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

PHASE3CompletedINTERVENTIONAL
Enrollment

716

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

December 22, 2020

Study Completion Date

April 9, 2024

Conditions
Brain Neoplasms
Interventions
DRUG

Nivolumab

DRUG

Temozolomide

RADIATION

Radiotherapy

OTHER

Nivolumab Placebo

Trial Locations (123)

1011

Local Institution - 0064, Lausanne

1090

Local Institution - 0061, Vienna

Local Institution - 0070, Brussels

1200

Local Institution - 0069, Brussels

1211

Local Institution - 0065, Geneva

2065

Local Institution - 0052, St Leonards

2100

Local Institution - 0084, Copenhagen

2170

Local Institution - 0049, Liverpool

3000

Local Institution - 0071, Leuven

3084

Local Institution - 0050, Heidelberg

3181

Local Institution - 0051, Prahran

4020

Local Institution - 0062, Linz

5000

Local Institution - 0085, Odense

6009

Local Institution - 0122, Nedlands

8091

Local Institution - 0063, Zurich

10032

Local Institution - 0015, New York

10065

Local Institution - 0024, New York

10126

Local Institution - 0091, Torino

13385

Local Institution - 0040, Marseille

15706

Local Institution - 0080, Santiago Compostela

18103

Local Institution - 0098, Allentown

19107

Local Institution - 0016, Philadelphia

20007

Local Institution - 0031, Washington D.C.

20089

Local Institution - 0127, Rozzano (milano)

20133

Local Institution - 0089, Milan

20246

Local Institution - 0057, Hamburg

21287

Local Institution - 0020, Baltimore

27710

Preston Robert Tisch Brain Tumor Center at Duke University, Durham

28009

Local Institution - 0077, Madrid

28041

Local Institution - 0076, Madrid

28204

Local Institution - 0032, Charlotte

29425

Local Institution - 0021, Charleston

31100

Local Institution - 0045, Toulouse

33136

Local Institution - 0087, Miami

33612

Local Institution - 0030, Tampa

35042

Local Institution - 0044, Rennes

35128

Local Institution - 0092, Padua

37232

Local Institution - 0008, Nashville

37403

Erlanger Oncology & Hematology - Univ. of TN, Chattanooga

40139

Local Institution - 0088, Bologna

40202

Local Institution - 0018, Louisville

43210

Local Institution - 0027, Columbus

44195

Local Institution - 0001, Cleveland

46014

Local Institution - 0079, Valencia

48149

Local Institution - 0054, Münster

48202

Local Institution - 0035, Detroit

49100

Local Institution - 0094, Petah Tikva

50937

Local Institution - 0131, Cologne

53100

Local Institution - 0090, Siena

53127

Local Institution - 0055, Bonn

54035

Local Institution - 0042, Nancy

59037

Local Institution - 0043, Lille

60528

Local Institution - 0053, Frankfurt am Main

60637

Local Institution - 0022, Chicago

63110

Local Institution - 0002, St Louis

64239

Local Institution - 0093, Tel Aviv

66205

Local Institution - 0060, Westwood

69120

Local Institution - 0056, Heidelberg

69394

Local Institution - 0041, Lyon

72076

Local Institution - 0059, Tübingen

75010

Local Institution - 0038, Paris

75651

Local Institution - 0039, Paris

79106

Local Institution - 0124, Freiburg im Breisgau

81675

Local Institution - 0130, Munich

84112

Local Institution - 0009, Salt Lake City

85013

Local Institution - 0003, Phoenix

90048

Cedars Sinai Medical Center, Los Angeles

91054

Local Institution - 0123, Erlangen

92123

Local Institution - 0029, San Diego

93053

Local Institution - 0058, Regensburg

95816

Local Institution - 0128, Sacramento

98122

Local Institution - 0005, Seattle

105229

Local Institution - 0095, Moscow

115478

Local Institution - 0097, Moscow

1040045

Local Institution - 0111, Chuo-ku

1138655

Local Institution - 0114, Bunkyo-ku

1628666

Local Institution - 0115, Shinjuku-ku

2520375

Local Institution - 0118, Sagamihara-shi

2608677

Local Institution - 0099, Chiba

3058576

Local Institution - 0116, Tsukuba

3501298

Local Institution - 0121, Hidaka-shi

4668560

Local Institution - 0110, Nagoya

5650871

Local Institution - 0112, Suita

5731191

Local Institution - 0104, Hirakata-shi

6068507

Local Institution - 0109, Kyoto

7008558

Local Institution - 0120, Okayama

7348551

Local Institution - 0100, Hiroshima

8608556

Local Institution - 0106, Kumamoto

8908520

Local Institution - 0102, Kagoshima

9200934

Local Institution - 0103, Kanazawa

9909585

Local Institution - 0117, Yamagata

35294-3410

Local Institution - 0023, Birmingham

90095-1769

Local Institution - 0010, Los Angeles

94143-0372

Local Institution - 0006, San Francisco

06520

Local Institution - 0004, New Haven

02215

Local Institution - 0011, Boston

Local Institution - 0028, Boston

08820

Local Institution - 0017, Edison

07601

Local Institution - 0012, Hackensack

75390-8575

Local Institution - 0025, Dallas

V5Z 4E6

Local Institution - 0046, Vancouver

M5G 2M9

Local Institution - 0048, Toronto

H3A 2B4

Local Institution - 0047, Montreal

0608648

Local Institution - 0101, Sapporo

650-0017

Local Institution - 0105, Kobe

181-8611

Local Institution - 0107, Mitaka-shi

612-8555

Local Institution - 0108, Kyoto

3015 GD

Local Institution - 0073, Rotterdam

1066 CX

Local Institution - 0075, Amsterdam

9713 AP

Local Institution - 0074, Groningen

3584 CX

Local Institution - 0072, Utrecht

0424

Local Institution - 0083, Oslo

80-214

Local Institution - 0086, Gdansk

02-781

Local Institution - 0132, Warsaw

08916

Local Institution - 0126, Badalona-barcelona

08035

Local Institution - 0078, Barcelona

08036

Local Institution - 0125, Barcelona

221 85

Local Institution - 0081, Lund

171 64

Local Institution - 0082, Solna

M20 4BX

Local Institution - 0066, Manchester

SM2 5PT

Local Institution - 0119, Sutton

G12 0YN

Local Institution - 0068, Glasgow

NW1 2BU

Local Institution - 0067, London

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY